Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Complementary use of the DNA methylation-based tumor classification by the Bethesda v3 classifier in routine diagnostics: evaluation in a series of 516 cases

Summary

This study evaluates the performance of the DNA methylation-based Bethesda Classifier v3 (Bv3) for central nervous system (CNS) tumor diagnosis. Bv3 was tested on 516 samples, including straightforward cases and diagnostically challenging cases previously unclassifiable by the Heidelberg Classifier v12.8. It achieved correct classification in 97% of straightforward cases and successfully classified 56% of complex cases, with a low misclassification rate of 4%. The findings suggest that Bv3 is a robust complementary tool for routine neuropathological diagnostics, even for samples with low DNA concentration.

Critical appraisal

Clinical. The integration of the Bethesda Classifier v3 into routine neuropathological diagnostics could significantly enhance diagnostic accuracy for CNS tumors, especially in complex cases where current methods fall short. By providing more precise classifications according to WHO2021 guidelines, this tool would enable better patient stratification and more informed therapeutic decisions. Clinical impact could be observed in the medium term (3-5 years) with gradual adoption in reference laboratories, potentially justifying clinical trials based on more precise molecular subtypes.

Molecular biology. This study validates the use of a DNA methylation-based approach for CNS tumor classification. The underlying technology is DNA methylation profiling, a molecular biology technique that provides crucial epigenetic information for tumor characterization. Bv3 demonstrated robust performance even with samples of lower DNA concentration or tumor purity, which is critical for clinical biopsies. This paves the way for more reliable and standardized molecular diagnostic tests with high analytical validity.

Bioinfo & AI. The Bethesda Classifier v3 is a machine learning tool that complements existing approaches. It was evaluated on diverse cohorts (516 cases), demonstrating its ability to handle case complexity and provide objective classifications. Its performance is benchmarked against another classifier (Heidelberg v12.8) and the WHO2021 classification. Its clinical deployment could streamline workflows by providing objective and reproducible classifications, thereby reducing diagnostic uncertainty and prioritizing cases for multidisciplinary tumor boards.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology